Moderna  
3Q Revenues: $1.9 billion (+6%) 
3Q Earnings: $13 million (loss of $3.6 billion 3Q23)
YTD Revenues: $2.3 billion (-44%)
YTD Loss: $2.4 billion (loss of $4.9 billion) 
Comments: The company reported $1.8 billion in Spikevax sales in the quarter, up 4 % which includes $1.2 billion of U.S. sales and $0.6 billion of international sales, driven by higher sales in the U.S. market following the earlier launch of the updated COVID-19 vaccine. RSV vaccine mRESVIA had $10 million in sales in the quarter, which were lower than anticipated.